Association between type 2 diabetes, curative treatment and survival in men with intermediate‐ and high‐risk localized prostate cancer
Objective To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa. Subjects and Methods The Pro...
Saved in:
| Published in | BJU international Vol. 121; no. 2; pp. 209 - 216 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Wiley Subscription Services, Inc
01.02.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Objective
To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa.
Subjects and Methods
The Prostate Cancer database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (n = 2210) for comparison with data on men with PCa only (n = 23 071). All men had intermediate‐ (T1–2, Gleason score 7 and/or prostate‐specific antigen [PSA] 10–20 ng/mL) or high‐risk (T3 and/or Gleason score 8–10 and/or PSA 20–50 ng/mL) localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate logistic regression was used to calculate the odds ratios (ORs) for receipt of curative treatment in men with and without T2DM. Overall survival, for up to 8 years of follow‐up, was calculated both for men with T2DM only and for men with T2DM and PCa.
Results
Men with T2DM were less likely to receive curative treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 0.69–0.87). The 8‐year overall survival rates were 79% and 33% for men with T2DM and high‐risk PCa who did and did not receive curative treatment, respectively.
Conclusions
Men with T2DM were less likely to receive curative treatment for localized intermediate‐ and high‐risk PCa. Men with T2DM and high‐risk PCa who received curative treatment had substantially higher survival times than those who did not. Some of the survival differences represent a selection bias, whereby the healthiest patients received curative treatment. Clinicians should interpret this data carefully and ensure that individual patients with T2DM and PCa are not under‐ nor overtreated. |
|---|---|
| AbstractList | Objective
To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa.
Subjects and Methods
The Prostate Cancer database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (n = 2210) for comparison with data on men with PCa only (n = 23 071). All men had intermediate‐ (T1–2, Gleason score 7 and/or prostate‐specific antigen [PSA] 10–20 ng/mL) or high‐risk (T3 and/or Gleason score 8–10 and/or PSA 20–50 ng/mL) localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate logistic regression was used to calculate the odds ratios (ORs) for receipt of curative treatment in men with and without T2DM. Overall survival, for up to 8 years of follow‐up, was calculated both for men with T2DM only and for men with T2DM and PCa.
Results
Men with T2DM were less likely to receive curative treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 0.69–0.87). The 8‐year overall survival rates were 79% and 33% for men with T2DM and high‐risk PCa who did and did not receive curative treatment, respectively.
Conclusions
Men with T2DM were less likely to receive curative treatment for localized intermediate‐ and high‐risk PCa. Men with T2DM and high‐risk PCa who received curative treatment had substantially higher survival times than those who did not. Some of the survival differences represent a selection bias, whereby the healthiest patients received curative treatment. Clinicians should interpret this data carefully and ensure that individual patients with T2DM and PCa are not under‐ nor overtreated. Objective: To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa. Subjects and Methods: The Prostate Cancer database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (n = 2210) for comparison with data on men with PCa only (n = 23 071). All men had intermediate-(T1-2, Gleason score 7 and/or prostate-specific antigen [PSA] 10-20 ng/mL) or high-risk (T3 and/or Gleason score 8-10 and/or PSA 20-50 ng/mL) localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate logistic regression was used to calculate the odds ratios (ORs) for receipt of curative treatment in men with and without T2DM. Overall survival, for up to 8 years of follow-up, was calculated both for men with T2DM only and for men with T2DM and PCa. Results: Men with T2DM were less likely to receive curative treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 0.69-0.87). The 8-year overall survival rates were 79% and 33% for men with T2DM and high-risk PCa who did and did not receive curative treatment, respectively. Conclusions: Men with T2DM were less likely to receive curative treatment for localized intermediate-and high-risk PCa. Men with T2DM and high-risk PCa who received curative treatment had substantially higher survival times than those who did not. Some of the survival differences represent a selection bias, whereby the healthiest patients received curative treatment. Clinicians should interpret this data carefully and ensure that individual patients with T2DM and PCa are not under-nor overtreated. Objective To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa. Subjects and Methods The Prostate Cancer database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (n = 2210) for comparison with data on men with PCa only (n = 23 071). All men had intermediate- (T1-2, Gleason score 7 and/or prostate-specific antigen [PSA] 10-20 ng/mL) or high-risk (T3 and/or Gleason score 8-10 and/or PSA 20-50 ng/mL) localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate logistic regression was used to calculate the odds ratios (ORs) for receipt of curative treatment in men with and without T2DM. Overall survival, for up to 8 years of follow-up, was calculated both for men with T2DM only and for men with T2DM and PCa. Results Men with T2DM were less likely to receive curative treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 0.69-0.87). The 8-year overall survival rates were 79% and 33% for men with T2DM and high-risk PCa who did and did not receive curative treatment, respectively. Conclusions Men with T2DM were less likely to receive curative treatment for localized intermediate- and high-risk PCa. Men with T2DM and high-risk PCa who received curative treatment had substantially higher survival times than those who did not. Some of the survival differences represent a selection bias, whereby the healthiest patients received curative treatment. Clinicians should interpret this data carefully and ensure that individual patients with T2DM and PCa are not under- nor overtreated. To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa.OBJECTIVETo investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa.The Prostate Cancer database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (n = 2210) for comparison with data on men with PCa only (n = 23 071). All men had intermediate- (T1-2, Gleason score 7 and/or prostate-specific antigen [PSA] 10-20 ng/mL) or high-risk (T3 and/or Gleason score 8-10 and/or PSA 20-50 ng/mL) localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate logistic regression was used to calculate the odds ratios (ORs) for receipt of curative treatment in men with and without T2DM. Overall survival, for up to 8 years of follow-up, was calculated both for men with T2DM only and for men with T2DM and PCa.SUBJECTS AND METHODSThe Prostate Cancer database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (n = 2210) for comparison with data on men with PCa only (n = 23 071). All men had intermediate- (T1-2, Gleason score 7 and/or prostate-specific antigen [PSA] 10-20 ng/mL) or high-risk (T3 and/or Gleason score 8-10 and/or PSA 20-50 ng/mL) localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate logistic regression was used to calculate the odds ratios (ORs) for receipt of curative treatment in men with and without T2DM. Overall survival, for up to 8 years of follow-up, was calculated both for men with T2DM only and for men with T2DM and PCa.Men with T2DM were less likely to receive curative treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 0.69-0.87). The 8-year overall survival rates were 79% and 33% for men with T2DM and high-risk PCa who did and did not receive curative treatment, respectively.RESULTSMen with T2DM were less likely to receive curative treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 0.69-0.87). The 8-year overall survival rates were 79% and 33% for men with T2DM and high-risk PCa who did and did not receive curative treatment, respectively.Men with T2DM were less likely to receive curative treatment for localized intermediate- and high-risk PCa. Men with T2DM and high-risk PCa who received curative treatment had substantially higher survival times than those who did not. Some of the survival differences represent a selection bias, whereby the healthiest patients received curative treatment. Clinicians should interpret this data carefully and ensure that individual patients with T2DM and PCa are not under- nor overtreated.CONCLUSIONSMen with T2DM were less likely to receive curative treatment for localized intermediate- and high-risk PCa. Men with T2DM and high-risk PCa who received curative treatment had substantially higher survival times than those who did not. Some of the survival differences represent a selection bias, whereby the healthiest patients received curative treatment. Clinicians should interpret this data carefully and ensure that individual patients with T2DM and PCa are not under- nor overtreated. To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa. The Prostate Cancer database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (n = 2210) for comparison with data on men with PCa only (n = 23 071). All men had intermediate- (T1-2, Gleason score 7 and/or prostate-specific antigen [PSA] 10-20 ng/mL) or high-risk (T3 and/or Gleason score 8-10 and/or PSA 20-50 ng/mL) localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate logistic regression was used to calculate the odds ratios (ORs) for receipt of curative treatment in men with and without T2DM. Overall survival, for up to 8 years of follow-up, was calculated both for men with T2DM only and for men with T2DM and PCa. Men with T2DM were less likely to receive curative treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 0.69-0.87). The 8-year overall survival rates were 79% and 33% for men with T2DM and high-risk PCa who did and did not receive curative treatment, respectively. Men with T2DM were less likely to receive curative treatment for localized intermediate- and high-risk PCa. Men with T2DM and high-risk PCa who received curative treatment had substantially higher survival times than those who did not. Some of the survival differences represent a selection bias, whereby the healthiest patients received curative treatment. Clinicians should interpret this data carefully and ensure that individual patients with T2DM and PCa are not under- nor overtreated. |
| Author | Zethelius, Björn Rudman, Sarah Van Hemelrijck, Mieke Stattin, Pär Adolfsson, Jan Garmo, Hans Crawley, Danielle Holmberg, Lars |
| Author_xml | – sequence: 1 givenname: Danielle orcidid: 0000-0001-7294-5634 surname: Crawley fullname: Crawley, Danielle email: Danielle.crawley@kcl.ac.uk organization: King's College London – sequence: 2 givenname: Hans surname: Garmo fullname: Garmo, Hans organization: King's College London – sequence: 3 givenname: Sarah surname: Rudman fullname: Rudman, Sarah organization: Guy's and St Thomas’ NHS Foundation Trust and King's College London's Comprehensive Biomedical Research Centre – sequence: 4 givenname: Pär surname: Stattin fullname: Stattin, Pär organization: Umeå University – sequence: 5 givenname: Björn surname: Zethelius fullname: Zethelius, Björn organization: Medical Products Agency – sequence: 6 givenname: Lars surname: Holmberg fullname: Holmberg, Lars organization: King's College London – sequence: 7 givenname: Jan surname: Adolfsson fullname: Adolfsson, Jan organization: Karolinska Institutet – sequence: 8 givenname: Mieke surname: Van Hemelrijck fullname: Van Hemelrijck, Mieke organization: King's College London |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28418195$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-144946$$DView record from Swedish Publication Index https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-336246$$DView record from Swedish Publication Index http://kipublications.ki.se/Default.aspx?queryparsed=id:137567310$$DView record from Swedish Publication Index |
| BookMark | eNp9kstuFDEQRS0URB6w4AeQJTYgpRO7291jL4fwViQ2AbGz3O7qjCf9GPyY0bBizYpv5EuozEyCFCnxxldXp0qlqntI9oZxAEKec3bC8Z3W83TCCynZI3LARSUywdn3vRvNVLVPDkOYM4ZGVT4h-7kUXHJVHpDf0xBG60x040BriCuAgcb1AmhOG2fQgXBMbfJILIFGDyb2MERqhoaG5JduaTrqBoomXbk4Qx3B94DFEf7--rMBZ-5yhtq7cEW70ZrO_YSGLvwYIlLUmsGCf0oet6YL8Gz3H5GL9-8uzj5m518-fDqbnmcWp2cZVw0waIScFDxvWsugkCpXsrSyqWrFWd3yFpiSk7yyleVcgrBVKWVTVsZMiiOSbduGFSxSrRfe9cav9Wic3llXqEALNRGyQP74Xv6t-zbVo7_UKemiqHJRPdj-P94nzYVQG_7Vlsdt_EgQou5dsNB1ZoAxBc2lVIUs8bqIvryDzsfkB9yV5koqmeO819SLHZVqPMPtADc3R-D1FrC4_-ChvUU409d50pgnvckTsqd3WOviJizRG9c9VLFyHazvb63ffP66rfgH8enfuQ |
| CitedBy_id | crossref_primary_10_1016_j_euros_2021_10_002 crossref_primary_10_1111_bju_13923 crossref_primary_10_3390_cancers13040875 crossref_primary_10_1002_ijc_31587 crossref_primary_10_15406_unoaj_2023_11_00334 |
| Cites_doi | 10.1002/cncr.22461 10.1016/j.urology.2008.05.037 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R 10.1016/0021-9681(87)90171-8 10.1093/ajcn/86.3.843S 10.1093/annonc/mdq443 10.1093/ije/dys068 10.1158/1055-9965.1646.13.10 10.1016/j.critrevonc.2005.08.003 10.1002/pds.1294 10.1016/S0022-5347(01)65964-0 10.1200/JCO.2006.10.3820 10.1080/08037050310025735 10.1111/bju.13404 10.1002/cncr.30506 10.1016/j.eururo.2016.08.003 10.1093/ije/dyv305 10.1158/1940-6207.CAPR-09-0188 10.1136/bmj.g1502 10.1002/cncr.25984 |
| ContentType | Journal Article |
| Copyright | 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd. BJUI © 2018 BJU International |
| Copyright_xml | – notice: 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd – notice: 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd. – notice: BJUI © 2018 BJU International |
| DBID | AAYXX CITATION NPM 7QP 7X8 ADTPV AOWAS D93 DF2 D8T ZZAVC |
| DOI | 10.1111/bju.13880 |
| DatabaseName | CrossRef PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic SwePub SwePub Articles SWEPUB Umeå universitet SWEPUB Uppsala universitet SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | CrossRef PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | Calcium & Calcified Tissue Abstracts MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-410X |
| EndPage | 216 |
| ExternalDocumentID | oai_swepub_ki_se_497483 oai_DiVA_org_uu_336246 oai_DiVA_org_umu_144946 28418195 10_1111_bju_13880 BJU13880 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Experimental Cancer Medicine Centre at King's College London – fundername: Stockholm Cancer Society – fundername: Västerbotten County Council – fundername: National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust – fundername: Swissbridge Foundation – fundername: Swedish Council for Working Life and Social Research – fundername: Swedish Research Council funderid: 825‐2012‐5047 |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION NPM 7QP AAMMB AEFGJ AGXDD AIDQK AIDYY 7X8 1OB ADTPV AOWAS D93 DF2 D8T ZZAVC |
| ID | FETCH-LOGICAL-c4660-19de0ed487312dfc0e3892985c8d6b910bf1fe098726c6c118e4c6588d56aa73 |
| IEDL.DBID | DR2 |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Mon Aug 25 03:27:57 EDT 2025 Thu Aug 21 06:36:36 EDT 2025 Thu Aug 21 06:38:56 EDT 2025 Fri Jul 11 08:32:54 EDT 2025 Fri Jul 25 05:56:23 EDT 2025 Wed Feb 19 02:42:54 EST 2025 Thu Apr 24 22:58:54 EDT 2025 Tue Jul 01 03:50:13 EDT 2025 Wed Jan 22 16:29:35 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | PCSM external beam radiotherapy ProstateCancer prostatectomy curative treatment diabetes |
| Language | English |
| License | 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4660-19de0ed487312dfc0e3892985c8d6b910bf1fe098726c6c118e4c6588d56aa73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-7294-5634 |
| OpenAccessLink | http://kipublications.ki.se/Default.aspx?queryparsed=id:137567310 |
| PMID | 28418195 |
| PQID | 1989827488 |
| PQPubID | 1026371 |
| PageCount | 8 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_497483 swepub_primary_oai_DiVA_org_uu_336246 swepub_primary_oai_DiVA_org_umu_144946 proquest_miscellaneous_1889385388 proquest_journals_1989827488 pubmed_primary_28418195 crossref_primary_10_1111_bju_13880 crossref_citationtrail_10_1111_bju_13880 wiley_primary_10_1111_bju_13880_BJU13880 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2018 |
| PublicationDateYYYYMMDD | 2018-02-01 |
| PublicationDate_xml | – month: 02 year: 2018 text: February 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Edgecliff |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2018 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2014; 348 1987; 40 2011; 117 2012 1999; 18 2016; 118 2013; 42 2006; 58 2004; 13 2011; 22 2017 2016; 71 2007; 86 2010; 3 2008; 72 2007; 109 1996; 156 2007; 25 2016; 45 2007; 16 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 Laukkanen JA (e_1_2_7_8_1) 2004; 13 e_1_2_7_25_1 e_1_2_7_24_1 e_1_2_7_23_1 e_1_2_7_22_1 e_1_2_7_21_1 e_1_2_7_20_1 29359530 - BJU Int. 2018 Feb;121(2):164-165 |
| References_xml | – volume: 86 start-page: s843 year: 2007 end-page: 57 article-title: Obesity, metabolic syndrome, and prostate cancer publication-title: Am J Clin Nutr – volume: 13 start-page: 47 year: 2004 end-page: 55 article-title: Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high‐stage and high‐grade clinical prostate cancer publication-title: Blood Press – volume: 42 start-page: 956 year: 2013 end-page: 67 article-title: Cohort profile: the national prostate cancer register of Sweden and prostate cancer data base Sweden 2.0 publication-title: Int J Epidemiol – volume: 45 start-page: 73 year: 2016 end-page: 82 article-title: Cohort profile update: the national prostate cancer register of Sweden and prostate cancer data base‐a refined prostate cancer trajectory publication-title: Int J Epidemiol – volume: 13 start-page: 1646 year: 2004 end-page: 50 article-title: Metabolic syndrome and the risk of prostate cancer in Finnish men: a population‐based study publication-title: Cancer Epidemiol Biomark Prev – volume: 118 start-page: 302 year: 2016 end-page: 6 article-title: Postoperative mortality 90 days after robot‐assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population‐based study publication-title: BJU Int – volume: 156 start-page: 127 year: 1996 end-page: 32 article-title: The impact of co‐morbidity on life expectancy among men with localized prostate cancer publication-title: J Urol – volume: 71 start-page: 618 year: 2016 end-page: 629 article-title: EAU‐ESTRO‐SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent publication-title: Eur Urol – volume: 109 start-page: 875 year: 2007 end-page: 81 article-title: Features of the metabolic syndrome and prostate cancer in African‐American men publication-title: Cancer – volume: 58 start-page: 60 year: 2006 end-page: 7 article-title: Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population‐based study publication-title: Crit Rev Oncol Hematol – volume: 348 start-page: g1502 year: 2014 article-title: Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes publication-title: BMJ – volume: 117 start-page: 3943 year: 2011 end-page: 52 article-title: Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates publication-title: Cancer – volume: 25 start-page: 3576 year: 2007 end-page: 81 article-title: A nomogram predicting 10‐year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer publication-title: J Clin Oncol – volume: 3 start-page: 279 year: 2010 end-page: 89 article-title: Finasteride modifies the relation between serum C‐peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial publication-title: Cancer Prev Res – volume: 72 start-page: 1252 year: 2008 end-page: 7 article-title: Detailed analysis of Charlson comorbidity score as predictor of mortality after radical prostatectomy publication-title: Urology – year: 2017 – volume: 22 start-page: 801 year: 2011 end-page: 7 article-title: Presence of the metabolic syndrome is associated with shorter time to castration‐resistant prostate cancer publication-title: Ann Oncol – volume: 16 start-page: 726 year: 2007 end-page: 35 article-title: The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months publication-title: Pharmacoepidemiol Drug Saf – volume: 40 start-page: 373 year: 1987 end-page: 83 article-title: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation publication-title: J Chronic Dis – volume: 18 start-page: 681 year: 1999 end-page: 94 article-title: Multiple imputation of missing blood pressure covariates in survival analysis publication-title: Stat Med – year: 2012 – ident: e_1_2_7_6_1 doi: 10.1002/cncr.22461 – ident: e_1_2_7_13_1 doi: 10.1016/j.urology.2008.05.037 – ident: e_1_2_7_20_1 doi: 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R – ident: e_1_2_7_3_1 – ident: e_1_2_7_14_1 doi: 10.1016/0021-9681(87)90171-8 – ident: e_1_2_7_5_1 doi: 10.1093/ajcn/86.3.843S – ident: e_1_2_7_25_1 – ident: e_1_2_7_4_1 – ident: e_1_2_7_10_1 doi: 10.1093/annonc/mdq443 – ident: e_1_2_7_16_1 doi: 10.1093/ije/dys068 – volume: 13 start-page: 1646 year: 2004 ident: e_1_2_7_8_1 article-title: Metabolic syndrome and the risk of prostate cancer in Finnish men: a population‐based study publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.1646.13.10 – ident: e_1_2_7_22_1 doi: 10.1016/j.critrevonc.2005.08.003 – ident: e_1_2_7_2_1 – ident: e_1_2_7_19_1 doi: 10.1002/pds.1294 – ident: e_1_2_7_24_1 – ident: e_1_2_7_11_1 doi: 10.1016/S0022-5347(01)65964-0 – ident: e_1_2_7_21_1 doi: 10.1200/JCO.2006.10.3820 – ident: e_1_2_7_7_1 doi: 10.1080/08037050310025735 – ident: e_1_2_7_26_1 doi: 10.1111/bju.13404 – ident: e_1_2_7_27_1 doi: 10.1002/cncr.30506 – ident: e_1_2_7_15_1 doi: 10.1016/j.eururo.2016.08.003 – ident: e_1_2_7_17_1 doi: 10.1093/ije/dyv305 – ident: e_1_2_7_18_1 – ident: e_1_2_7_9_1 doi: 10.1158/1940-6207.CAPR-09-0188 – ident: e_1_2_7_23_1 doi: 10.1136/bmj.g1502 – ident: e_1_2_7_12_1 doi: 10.1002/cncr.25984 – reference: 29359530 - BJU Int. 2018 Feb;121(2):164-165 |
| SSID | ssj0014665 |
| Score | 2.2476656 |
| Snippet | Objective
To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as... To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is... Objective To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as... Objective: To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as... OBJECTIVE: To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as... |
| SourceID | swepub proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 209 |
| SubjectTerms | curative treatment Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) external beam radiotherapy PCSM Prostate cancer Prostate-specific antigen ProstateCancer prostatectomy Survival |
| Title | Association between type 2 diabetes, curative treatment and survival in men with intermediate‐ and high‐risk localized prostate cancer |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbju.13880 https://www.ncbi.nlm.nih.gov/pubmed/28418195 https://www.proquest.com/docview/1989827488 https://www.proquest.com/docview/1889385388 https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-144946 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-336246 http://kipublications.ki.se/Default.aspx?queryparsed=id:137567310 |
| Volume | 121 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFH6ahoS4bPwcgTEZBIgDqZI2TR1xahnVNAkOaEM7TLIS20FlLJ3a5rITZ078jfwlfM9JrA02hDjVSl5b-_k9-3v282ei5wXmHC1LeJqNkzAZcSkzJoxtHpVZiV4vXZbvh3TvMNk_Gh6t0ZvuLEzDD-EX3Ngz3HjNDp4XywtOXnypezFTmWD85VwtBkQfPXUUBgB3jSQ-UQXg9JZViLN4_Dcvz0V_AEzPHnoZuLqZZ7pJx12dm4STk169Knr6_Dc6x_9s1G3aaBGpGDcmdIfWbHWXbr5v99zv0fcLPSjatC7BK7eiL7qV29dC1w2FuPCZ6yKvjFjWGIpgzGJWCTwUvOwrmKJi4Y6srOzPbz-cINMmo8yZ7sLNr7Nza8QZn0mBlNBsnIv7dDB9d_B2L2xvcAg19B-FcWZsZA2CokHcN6WOLPBRP5NDLU1aAKkUZVzaKJOjfqpTjWDHJhqYSJphmuejwQNar-aVfUgiyRC3aj2KckS0Mi0gUiJyZHq7XGZ5FtCrriuVbtnN-ZKNr6qLcqBa5VQb0DMvetZQelwltN3Zg2q9eqk4v0wijJcyoKf-NfyRN1nyys5ryEggQGAgltlq7Mj_C6BAzPuWAb1sDMu_YZLv3dmnsZovPqv6FJVI0OI0oBd_FazVAACE5a76wfbRCUpWQVeJHEBNzvyub7ia7B-6wqN_F31Mt4AjZZPMvk3rq0VtnwCrrYodujGe7E6mO845fwEO4UBs |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgGX8iwEChgEiEOzSnazWUfiUh7VUtoe0Bb1gqzEdtBSmq22m0tPnDnxG_klfOMkVgsFIU5rJbO7fszY34zHn4meFFhztCxhaTZOwmTEpcyYMLZ5VGYlRr10Wb676Xgv2dof7i_Ri-4sTMMP4QNubBluvmYD54D0KSsvPte9mLlMLtBFvtHbOVTvPXkUpgB3kSQ-UQkg9ZZXiPN4_FfPrka_QUzPH3oWurq1Z_Mqfexq3aScHPTqRdHTJ78QOv5vs67RSgtKxUajRddpyVY36NJOu-1-k76dGkTRZnYJDt6KvuiCt-tC1w2LuPDJ6yKvjDiuMRtBn8W0EngoOPIrmKVi7k6tLOyPr9-dIDMno8zJ7sItsdMTa8QRH0uBlNCsn_NbNNl8M3k1DttLHEKNAYjCODM2sgZ-0SDum1JHFhCpn8mhliYtAFaKMi5tlMlRP9Wphr9jEw1YJM0wzfPRYJWWq1ll75BIMriuWo-iHE6tTAuIlHAemeEul1meBfS8G0ulW4Jzvmfji-ocHXStcl0b0GMvetSwepwntNYphGoN-1hxipmEJy9lQI_8a5gk77PklZ3VkJEAgYBBLHO7UST_L0ADMW9dBvSs0Sz_hnm-X08_bKjZ_JOqD1GJBC1OA3r6V8FaDYBBWO68H2wfHaBkFfoqkQN0k9O_Pzdcvdzac4W7_y76kC6PJzvbavvt7rt7dAWwUja57Wu0vJjX9j6g26J44Cz0J8d5QxU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxEB6VIlVceD8WChgEiAMb7SabjVecCiEqBSqEWtQDkrXrB0pbNlGavfTEmRO_kV_CN96HWigIcYq1O0ns8Yz9jT3-TPSowJyjpYOn2TgJkxGXMmPC2OaRyxx63fks3-10czfZ2hvurdDz9ixMzQ_RLbixZ_jxmh18btwJJy_2q17MVCbn6HySRpJNevyh447CCODvkcQn6gCg3tAKcRpP99XTk9FvCLOjDz2NXP3UM7lEn9pK1xknB71qWfT08S98jv_Zqst0sYGkYqO2oSu0YsurtPau2XS_Rt9OdKFo8roEL92KvmiXbp8JXdUc4qJLXRd5acRRhbEI1iympcBDweu-gjkqFv7MytL--PrdCzJvMsqc6i78BDs9tkbM-VAKpIRm61xcp53Jq52Xm2FzhUOoof8ojDNjI2sQFQ3ivnE6sgBI_UwOtTRpAahSuNjZKJOjfqpTjWjHJhqgSJphmuejwQ1aLWelvUUiyRC4aj2KcoS0Mi0g4hA6Mr9dLrM8C-hp25VKN_TmfMvGoWrDHKhWedUG9LATndecHmcJrbf2oBq3PlKcYCYRx0sZ0IPuNRySd1ny0s4qyEhAQIAglrlZ21H3L8ACMW9cBvSkNqzuDbN8j6cfN9Rs8VlVX1CJBC1OA3r8V8FKDYBAWO6sH2weHaBkFXSVyAHU5M3vzw1XL7Z2feH2v4vep7X344l6-3r7zR26AEwp68T2dVpdLip7F7htWdzz_vkT-cFBzQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+type+2+diabetes%2C+curative+treatment+and+survival+in+men+with+intermediate%E2%80%90+and+high%E2%80%90risk+localized+prostate+cancer&rft.jtitle=BJU+international&rft.au=Crawley%2C+Danielle&rft.au=Garmo%2C+Hans&rft.au=Rudman%2C+Sarah&rft.au=Stattin%2C+P%C3%A4r&rft.date=2018-02-01&rft.issn=1464-4096&rft.eissn=1464-410X&rft.volume=121&rft.issue=2&rft.spage=209&rft.epage=216&rft_id=info:doi/10.1111%2Fbju.13880&rft.externalDBID=10.1111%252Fbju.13880&rft.externalDocID=BJU13880 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |